Eli Lilly and Co (NYSE:LLY) released Thursday topline results from two phase 3 trials. The drugmaker evaluated once-weekly insulin efsitora alfa (efsitora) in type 2 diabetes patients using insulin for the first time (insulin naïve) and those who require multiple daily insulin injections.  In the treat-to-target clinical trials, efsitora showed non-inferior A1C reduction compared to the most commonly used daily basal insulins globally. QWINT-2 evaluated the efficacy and safety of once-weekly efsitora compared to once-daily insulin degludec for 52 weeks.  The trial met its primary endpoint of non-inferior A1C reduction with efsitora compared ...